Global News

PTC Therapeutics announces milestone in SMA collaboration

Tuesday, August 13, 2013 10:00 AM

PTC Therapeutics has announced the selection of a development candidate in its spinal muscular atrophy (SMA) collaboration with Roche and the SMA Foundation. The achievement of the milestone triggers a $10 million payment to PTC from Roche.

More... »

Sciformix expands offices to the Philippines

Tuesday, August 13, 2013 09:30 AM

Sciformix, a Scientific Process Organization (SPO), has opened offices in Manila, the Philippines. Sciformix intends to add more than 200 employees in the Philippines, said Manish Vinayak Soman, Sciformix president and chief executive officer.

More... »

Quest Diagnostics launches opioid therapy genetic test

Monday, August 12, 2013 04:23 PM

Quest Diagnostics, a provider of diagnostic information services, has launched a lab-developed genetic test to aid the delivery of personalized opioid pain-relieving treatment. It is the first clinical lab to offer testing for variants in all cytochrome P450 (CYP450) genes known to influence the CYP450 enzyme system, which affects metabolism of opioids and other medications.

More... »

Anne Lindblad promoted to president and CEO of EMMES

Monday, August 12, 2013 04:18 PM

EMMES has promoted executive vice president Dr. Anne Lindblad to president and chief executive officer. Lindblad replaces Dr. Donald (Don) Stablein, who has been named past president. Stablein, who joined the company in 1980, has been president/CEO since 1992. In his new role as past president, he will continue to provide project support and will be an ambassador for EMMES.

More... »

Roche launches GS FLX+ System software update

Monday, August 12, 2013 03:37 PM

Roche has launched a software update that extends the range of amplicon lengths available for targeted next-generation sequencing studies on the 454 GS FLX+ System. The latest software enables sequencing of amplicons up to 800bp while maintaining >99% accuracy over the length of the read.

More... »

Stem Cell Therapeutics acquires license option

Monday, August 12, 2013 01:15 PM

Stem Cell Therapeutics (SCT), a biopharmaceutical company developing cancer stem cell-related therapeutics, has entered into an option agreement to exclusively license worldwide rights to a series of prostate cancer stem cell assets from the University of York, U.K. The assets originate from research funded by and conducted at Yorkshire Cancer Research (YCR) under the direction of professor Norman Maitland.

More... »

WorldCare Clinical launches oncology imaging studies service

Monday, August 12, 2013 01:14 PM

CRO WorldCare Clinical (WCC) has launched a service that enables simultaneous capture and analysis of both standard tumor assessments, including Response Evaluation Criteria in Solid Tumors (RECIST) and the immune-related response criteria (irRC). WCC’s method has been validated and is being used to evaluate new immune-related treatments.  

More... »

Nuevolution launches collaboration

Monday, August 12, 2013 01:12 PM

Nuevolution is collaborating with Duke University, the Howard Hughes Medical Institute and Lexicon Pharmaceuticals for the investigation of the biological mechanism of action of a specified GPCR drug target. The Principal Investigator for Duke University and the Howard Hughes Medical Institute is Robert J. Lefkowitz, a Duke faculty member, HHMI employee and Nobel Laureate in Chemistry 2012.

More... »

Catabasis announces successful phase I trial

Friday, August 9, 2013 02:09 PM

Catabasis Pharmaceuticals has announced preliminary data from a phase I trial of CAT-2003, an oral SMART Linker conjugate constructed using the company's proprietary technology, demonstrated a significant reduction in fasting and post-prandial triglyceride levels. CAT-2003 also had positive effects on other biomarkers, including reductions in apolipoprotein C-III (ApoC-III), a negative regulator of lipoprotein lipase, and apolipoprotein B (ApoB), the lipoprotein associated with VLDL and LDL cholesterol. In addition, reductions in plasma PCSK9 levels and LDL cholesterol were observed.

More... »

Boehringer, Lilly enroll first patient in type 2 diabetes trial

Friday, August 9, 2013 02:07 PM

Boehringer Ingelheim Pharmaceuticals and Eli Lilly have announced enrollment of the first patient into a cardiovascular (CV) and renal outcomes trial for linagliptin (tradjenta) tablets.

More... »